At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 60 enrolled
Drug / intervention
LY3202328 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
In Brief
A Phase 1 clinical trial evaluating LY3202328, Placebo, and 2 other interventions for Dyslipidemias. Completed, enrolled 60 participants across 4 sites.
Detailed Summary
The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedMar 2016
Primary CompletionFeb 2017
TodayJul 2026
First PostedMar 21, 2016
Enrollment StartMar 1, 2016
Primary CompletionFeb 15, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.3 years ago
Interventions
LY3202328drug
Administered orally
Placebodrug
Administered orally
Atorvastatindrug
Administered orally
Simvastatindrug
Administered orally